Article
Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Molecular cancer research : MCR - 1 Nov 2008
Anglesio Michael S, Arnold Jeremy M, George Joshy, Tinker Anna V, Tothill Richard, Waddell Nic, Simms Lisa, Locandro Bianca, Fereday Sian, Traficante Nadia, Russell Peter, Sharma Raghwa, Birrer Michael J, deFazio Anna, Chenevix-Trench Georgia, Bowtell David D L
Abstract excerpt
Approximately, 10% to 15% of serous ovarian tumors fall into the category designated as tumors of low malignant potential (LMP). Like their invasive counterparts, LMP tumors may be associated with extraovarian disease, for example, in the peritoneal cavity and regional lymph nodes. However, unlike typical invasive carcinomas, patients generally have a favorable prognosis. The mutational profile also differs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.